Introducing Our Newest Scientific Advisory Board Member

by | May 27, 2015 | 0 comments

Scott Stromatt Headshot 2Dr. Stromatt has conducted over 55 Phase 1 to Phase 4 clinical trials in a wide variety of clinical indications, including oncology, rheumatology, pulmonology, gastroenterology, and neurology. In the field of neurology, he ran clinical trials with a novel growth factor for Lou Gehrig’s disease, or amyotrophic lateral sclerosis. He has worked on various regulatory filings including INDs, NDAs, BLAs, and MAAs. Additionally, he has experience in medical affairs with extensive market and brand management support.

Currently, Dr. Stromatt is the Chief Medical Officer at Emergent BioSolutions in Seattle, WA – a biotechnology company focused on oncology, autoimmune disease, and infectious diseases.

Learn more on this topic

Related Blog Posts

Dr. Sean Ekins named C.S.O. of HNF

We are delighted to announce that after volunteering for HNF for the past year Dr. Sean Ekins, Ph.D, D.Sc. will officially become our CSO responsible for overseeing the TRIAD program, directing our scientific advisory board, and communicating our research initiatives to the scientific community. In addition he serves as the Principal Investigator of the clinical Global Registry for Inherited Neuropathy (GRIN).

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news